TrialHuman vaccines & immunotherapeutics2024

Immune persistence and booster response of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) 5 years after primary vaccination of adults at ≥56 years of age.

Corwin A Robertson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.